🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nagpur
Clinical trial register · India

Clinical Trials in Nagpur

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 17 Ahmedabad 16 Bangalore 15 Bhubaneswar 14 Hyderabad 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Eli Lilly and Company14 Bristol-Myers Squibb12 Novo Nordisk A/S9 Sanofi6 Clear sponsor filter
Site location
New Delhi17 Ahmedabad16 Bangalore15 Bhubaneswar14 Hyderabad14
All 61 locations
Target enrolment
to
14 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Eli Lilly and Company
Phase 3
2,001
Aligarh, Baroda, Guntur, Hubli, Jaipur, Mysore, Nagpur, Trivandrum
2026-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Bengaluru, Bhubaneswar, Guntur, Nagpur, New Delhi, Pune, Raipur, Rishikesh
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Guntur, Guwahati, Hyderabad, Mandya, Mumbai, Mysore, Nagpur, Nashik
2026-02-06
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
Eli Lilly and Company
Phase 3
1,035
Bangalore, Belgavi, Lucknow, Nagpur, Pune, Ulhasnagar
2025-12-15
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Aligarh, Jaipur, Kolkata, Kozhikode, Nagpur, Nashik, New Delhi, Rishikesh
2025-10-31
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Ahmedabad, Belagavi, Belgavi, Bhubaneswar, Chandigarh, Chennai, Hyderabad, Nagpur
2025-09-30
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belagavi, Belgavi, Jaipur, Kanpur, Kozhikode, Lucknow, Nagpur, Nashik
2025-09-02
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
Eli Lilly and Company
Phase 3
3,127
Guntur, Bangalore, Mysore, Nagpur, Pune
2023-06-05
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Ahmedabad, Bikaner, Hyderabad, Lucknow, Ludhiana, Mumbai, Nagpur, New Delhi
2022-10-11
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
Thiruvananthapuram, Mumbai, Nagpur, Nashik, New Delhi
2021-12-20
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bangalore, Thiruvananthapuram, Mumbai, Nagpur, Nashik, Pune, Hyderabad
2021-10-04
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326Chronic Migraine
Eli Lilly and Company
Phase 3
312
Ahmedabad, Gurugram, Kanpur, Mangalore, Nagpur, New Delhi, Pune
2020-11-25
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Ahmedabad, Bangalore, Hyderabad, Jaipur, Ludhiana, Nagpur, Noida, Pune
2018-07-18
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286Episodic Migraine
Eli Lilly and Company
Phase 3
533
Mangalore, Nagpur, New Delhi, Pune
2018-03-14
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/nagpur

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.